Seres Q2 2026 Earnings: A $25 Million VOWST Gain Drives Quarterly Profit

Seres Therapeutics (Nasdaq: MCRB) reported Q2 2026 grant revenue of $736,000, versus no revenue in Q2 2025, while diluted EPS was $0.47 compared with a loss of $2.27 per share. A $25 million gain related to the VOWST business sale produced quarterly net income, but the company still recorded a $21.3 million operating loss and expects its available funding to last only through Q1 2027.

Core Financial Results

Lower research, administrative, and manufacturing-service expenses reduced Seres’ operating cost base. R&D expense fell 29.4% because of lower personnel, facility, transition-service, and SER-155 costs, while G&A expense declined 31.1% on similar cost reductions.

However, a $5.8 million impairment charge related to the early termination of leased space offset part of those savings. Consequently, total operating expenses declined by a more modest 11.5%, and the business remained loss-making at the operating level.

All figures in the table are GAAP results for the three months ended June 30.

Pipeline and Business Updates

SER-155 produced an 80% immunosuppressive-free clinical response rate at day 15 in an investigator-sponsored study of immune checkpoint inhibitor-related enterocolitis, or irEC. Twelve of 15 participants with moderate-to-severe irEC achieved at least a one-grade improvement in diarrhea symptoms without immunosuppressive therapy.

The open-label study also found SER-155 was generally well tolerated, with no identified safety concerns and no serious adverse events assessed as treatment-related. The small study supports further evaluation, but Seres is still determining the clinical development path and seeking potential partners, including companies with immune checkpoint inhibitor franchises.

In its other lead indication, SER-155 remains ready for a Phase 2 study aimed at preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants. The program has Breakthrough Therapy and Fast Track designations, but further development remains dependent on securing funding.

Seres is also conducting IND-enabling work for SER-603 in inflammatory bowel disease and seeking collaborators. For SER-428, an oral liquid formulation based on SER-155 strains, the company is designing a Phase 1b open-label study in medical ICU patients at high risk of infection.

A One-Time VOWST Gain Turned an Operating Loss Into Net Income

The main distinction in the quarter was between reported net income and underlying operations. Seres recorded a $25 million gain after Nestlé Health Science agreed to buy out potential future VOWST net-sales milestones. That gain more than offset the $21.3 million operating loss and resulted in net income of $4.6 million.

The transaction did not represent revenue from Seres’ current pipeline. It monetized contingent payments associated with VOWST, which Seres sold to Nestlé in 2024. The quarterly profit therefore does not indicate that the company’s continuing research operations reached profitability.

The accounting gain and cash collection also occurred on different schedules. Seres recognized the full $25 million gain in Q2, while the first $12.5 million installment was received on July 1 and the remaining $12.5 million is expected on October 1.

Cash Runway Outlook

Cash and cash equivalents declined from $45.8 million at December 31, 2025, to $15.6 million at June 30, 2026. The company’s runway estimate incorporates both installments from the VOWST milestone buyout but does not assume proceeds from future partnerships or other capital sources.

Seres is also reducing facility obligations. Combined current and long-term operating lease liabilities fell from approximately $83.0 million at the end of 2025 to $56.6 million at June 30, 2026, following the restructuring of its CambridgePark Drive lease.

On July 31, Seres agreed to terminate its Sidney Street lease early, eliminating the remaining obligations after December 31, 2026 in exchange for unspecified consideration. The company expects this action to lower facility-related cash costs beginning in 2027, with the accounting impact scheduled to appear in Q3 2026 results.

Risks Investors Need to Watch

• Additional financing remains necessary: The projected runway extends only through Q1 2027, while advancement of SER-155 and other programs depends on partnerships or new capital.
• SER-155 evidence remains preliminary: The irEC results came from an open-label study with 15 participants. Seres must still determine and fund the next development stage.
• Quarterly profitability was transaction-driven: The $25 million VOWST gain was not generated by continuing operations, which recorded a $21.3 million loss.
• Cost savings take time to reach cash flow: The latest lease termination is expected to reduce costs beginning in 2027, while its accounting effects and associated consideration will first be reflected in Q3 2026.

Summary

Seres’ Q2 2026 net income was driven by the one-time monetization of future VOWST milestones rather than profitability from continuing operations. Expense reductions narrowed the operating loss, and early SER-155 irEC data provided clinical support for further development. The central issue now is whether Seres can secure partners or additional financing before its projected funding runway ends, while converting preliminary SER-155 results into a larger clinical program.